Payment overview · 2025
General Payments
$134.62
7 reported records · 3 companies
Healthcare provider profile · identity verified
Anupreet Kaur, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CIRCLEVILLE, OH · NPI 1417244393
Verified facts
What the public records show
CMS Open Payments records show Anupreet Kaur, M.D. received $134.62 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 71.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.74 | 71.9% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.25 | 17.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.63 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $134.62 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $96.74 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $96.74 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 381 | 120 |
| Omeprazole | Omeprazole | 378 | 108 |
| Losartan Potassium | Losartan Potassium | 316 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 82 |
| Lisinopril | Lisinopril | 256 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 53 |
| Simvastatin | Simvastatin | 184 | 55 |
| Gabapentin | Gabapentin | 172 | 58 |
| Metformin Hcl | Metformin Hcl | 172 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 66 |
| Carvedilol | Carvedilol | 155 | 51 |
| Furosemide | Furosemide | 150 | 46 |
| Potassium Chloride | Potassium Chloride | 140 | 44 |
| Sertraline Hcl | Sertraline Hcl | 135 | 40 |
| Montelukast Sodium | Montelukast Sodium | 134 | 46 |
| Alendronate Sodium | Alendronate Sodium | 124 | 43 |
| Allopurinol | Allopurinol | 117 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 35 |
| Prednisone | Prednisone | 102 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 32 |
| Metformin Hcl Er | Metformin Hcl | 100 | 40 |
| Trazodone Hcl | Trazodone Hcl | 98 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 44 |
| Glimepiride | Glimepiride | 90 | 27 |
| Bupropion Xl | Bupropion Hcl | 80 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 23 |
| Famotidine | Famotidine | 79 | 25 |
| Celecoxib | Celecoxib | 75 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 22 |
| Buspirone Hcl | Buspirone Hcl | 65 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 15 |
| Meloxicam | Meloxicam | 62 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 21 |
| Eliquis | Apixaban | 58 | 19 |
| Cephalexin | Cephalexin | 57 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 13 |
| Spironolactone | Spironolactone | 56 | 17 |
| Tramadol Hcl | Tramadol Hcl | 56 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 46 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Januvia | Sitagliptin Phosphate | 51 | 21 |
| Lorazepam | Lorazepam | 51 | 20 |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Finasteride | Finasteride | 50 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Ozempic | Semaglutide | 49 | 14 |
| Alprazolam | Alprazolam | 48 | 15 |
| Jardiance | Empagliflozin | 47 | 13 |
| Methylprednisolone | Methylprednisolone | 46 | 41 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Fenofibrate | Fenofibrate | 45 | 13 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Mounjaro | Tirzepatide | 42 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 15 |
| Nifedipine Er | Nifedipine | 38 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 12 |
| Synthroid | Levothyroxine Sodium | 35 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Valsartan | Valsartan | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | 11 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 24 | suppressed |
| Azithromycin | Azithromycin | 24 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Fluconazole | Fluconazole | 16 | 14 |
| Nystatin | Nystatin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $134.62 · 7 records | ABBVIE INC. | QULIPTA, UBRELVY, Veozah, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error